Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
Date:12/10/2008

since several batches of product that were manufactured during the latter part of the second quarter were not shipped until the third quarter, when these revenues will be recorded.

Total costs and expenses decreased $1,954,000 to $6,491,000 in the second quarter of FY 2009 from $8,445,000 in the same prior year quarter, a decrease of 23%. The decrease was primarily related to planned reductions in R&D costs associated with Peregrine's preclinical programs. These reductions were implemented to maximize the R&D resources available to advance the company's priority clinical product candidates bavituximab and Cotara(R). R&D expenses were $4,301,000 in the second quarter of FY 2009, compared to $5,100,000 in the second quarter of FY 2008. The decrease in R&D expense was achieved despite an increase in clinical activity during the quarter. SG&A expenses were down $416,000 to $1,527,000 for the second quarter of FY 2009 compared to $1,943,000 for the comparable period in FY 2008, a decrease of 21%. This decrease reflects a reduction in SG&A expenses across the board, reflecting the company's focus on stringent management of all discretionary expense categories.

At October 31, 2008, the company had $8,210,000 in cash and cash equivalents. After the close of the quarter, on December 9, 2008, Peregrine entered into an agreement for a non-convertible term loan with an initial tranche of $5 million that will be funded upon closing, with an option to acquire a second $5 million tranche in the future, upon Peregrine's satisfaction of certain additional conditions.

"This past quarter was highlighted by significant milestones for both our bavituximab cancer and anti-viral programs," said Steven W. King, president and CEO of Peregrine. "For the first time, we reported patient enrollment underway in three bavituximab Phase II cancer trials, along with encouraging updated results from o
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
8. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
9. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
10. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
11. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... 2014 There has been a sharp increase in ... Center using MyChart, the online, interactive service that allows ... their healthcare providers, schedule appointments, and renew prescriptions. , ... using MyChart each year increased five-fold, while ... than 10-fold, according to a study by Dr. ...
(Date:7/9/2014)... watching World Cup highlights, Brian Williams refreshing old school ... positions on railings. A University of Colorado Cancer Center ... shows that YouTube also allows researchers, journals, and health ... of skin cancer and prevention. , "No matter what ... how we communicate around the world," says Chante Karimkhani, ...
(Date:7/9/2014)... the most important organs in the human body. Its ... properly this is its synthesis function and ... this is its detoxification function. Lack of exercise and ... the liver. The resulting diseased cells can lead to ... failure. According to the German Liver Foundation, over five ...
(Date:7/9/2014)... kidney and heart disease have raised concerns about the ... in the first study to look closely at this ... the University of Pennsylvania report that older kidney donors ... cardiovascular health as very healthy older people who did ... increasing organ transplant waitlists, the authors of the study ...
(Date:7/9/2014)... diseases has risen dramatically in Western societies. One frequently ... microorganisms and have fewer infections than previous generations, thereby ... by researchers at Sahlgrenska Academy, University of Gothenburg, monitored ... of the immune system in relation to allergic disease. ... the Vstra Gtaland Region, half of them on farms ...
Breaking Medicine News(10 mins):Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2
... ... important questions to ask when choosing an alcohol rehab centre. , ... London, UK (PRWEB) June 17, 2009 -- Linwood Group announce that there ... in getting someone who is struggling with drink on the road to recovery. Having treatment in ...
... ... of leading cardiovascular disease centers in the United States exploring the efficacy of a ... treatment of patients with advanced congestive heart failure (CHF) who are on the waiting ... ...
... Health reform must deliver "evolutionary change" says new leader of ... J. James Rohack, M.D., a cardiologist from Bryan, Texas, was ... Association (AMA), the nation,s largest and most influential physician organization. ... ) , , In his inaugural address as ...
... , Independence Blue Cross and Philadelphia Business Journal to ... June 16 Americans spend more ... costs continuing to climb, many employers are looking for ways to ... In conjunction with Philadelphia Business Journal, Independence Blue Cross (IBC) is ...
... statin drugs, such as Lipitor (atorvastatin), does not lower the ... of more than 3,000 Group Health patients published online on ... ,s June 20 print issue. "Prior research based on ... statins as a way to prevent and treat infections including ...
... , Reporting System Provides Information to Improve Quality of , ... , WASHINGTON, June 16 URAC , ... CARF International , a premier, global, independent accreditor ... for case management professionals. The uSPEQ(R)/URAC Participant Experience ...
Cached Medicine News:Health News:Linwood Group Research Suggests 3 Questions Everyone Should Ask When Choosing an Alcoholic Residential Centre 2Health News:AGH Joins Select Group of Medical Centers in Study of Promising New Technology for Treatment of Heart Failure 2Health News:AGH Joins Select Group of Medical Centers in Study of Promising New Technology for Treatment of Heart Failure 3Health News:AGH Joins Select Group of Medical Centers in Study of Promising New Technology for Treatment of Heart Failure 4Health News:AMA Inaugurates J. James Rohack as President 2Health News:Employee Health and Reducing Health Care Costs Focus of Working Wellness Expo June 17 2Health News:Employee Health and Reducing Health Care Costs Focus of Working Wellness Expo June 17 3Health News:Statins don't lower risk of pneumonia in elderly 2Health News:URAC and CARF International Announce New Survey Tool for Health Care Case Management Studies 2Health News:URAC and CARF International Announce New Survey Tool for Health Care Case Management Studies 3Health News:URAC and CARF International Announce New Survey Tool for Health Care Case Management Studies 4
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... ... Meeting - A cumulative forty-five percent (45%) of patients ... medoxomil), and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) achieved ... mm Hg) (placebo:1.4%)., - Eight out of 10 (cumulative 81%) patients with ...
... La ... ... 14 /PRNewswire-,FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a,biopharmaceutical ... research organization, today announced,that an agreement has been executed licensing classes ...
Cached Medicine Technology:New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 2New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 3New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 4New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 5New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 7Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 2Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 3Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: